Heated Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Peritoneal Cancer

Primary Objectives: To determine the maximum tolerated dose (MTD) of carboplatin given as HIPEC for primary treatment of women with advanced ovarian, peritoneal, and fallopian tube cancers. Secondary Objectives: 1. To determine the dose limiting toxicities of HIPEC carboplatin. 2. To describe the pharmacokinetic profile of HIPEC carboplatin. 3. To quantify changes in tissue temperature during HIPEC and compare to conventional temperature measures (esophageal and bladder). 4. To describe the extent of thermal damage and DNA platinum adduct formation in tissues resulting from HIPEC carboplatin. OUTLINE: This is a dose escalation study. Patients receive hyperthermic carboplatin intraperitoneally over 60 minutes during the planned surgical cytoreductive procedure.